Atopic dermatitis (AD) is a chronic inflammatory skin disease that is characterized by intense itching and recurrent eczematous lesions. The epidermal thickness with cutaneous hypersensitivity in AD is associated with increased serum immunoglobulin E (IgE) levels and infiltration of inflammatory cells including eosinophils, mast cells and basophils. Chronic exposure to the allergens will cause cross-linking of the IgEs and eventual degranulation of mast cells and basophils and release of histamine and other endogenous inflammatory pruritic agents. As current treatment regimens of AD represent a therapeutic challenge, there is a growing interest in cytokine-targeted therapies that could improve the therapeutic armamentarium for AD. To understand the mechanisms of the onset and development of this disease, appropriate animal models are essential.
Redoxis provides a Hapte-induced AD model based on Haptenogenic Oxazolone and offers a wide readout of cytokines activation as well as analysis of histology markers. For more detailed information on our model, see the specific disease information sheet.